The board of directors of biopharmaceutical company AbbVie Inc (NYSE:ABBV) approved a quarterly cash dividend of USD0.71 per share of the company's stock, it declared on Friday.
This cash dividend is due on 15 February 2018 to shareholders of record at the close of business as of 12 January 2018.
AbbVie added that its new quarterly cash dividend is higher by 11% from the prior USD0.64 per share dividend. Since its inception in 2013, it has increased its dividend by more than 77%.
According to AbbVie, its mission is to use its expertise, dedicated people and unique approach to innovation to markedly improve treatments across four primary therapeutic areas: immunology, oncology, virology and neuroscience.
Danaher Corporation announces quarterly cash dividend
Abbott announces quarterly common dividend
Bruker expands Preclinical Imaging Portfolio with acquisition of Spectral Instruments Imaging
Fusion Antibodies announces receipt of follow-on project and provides R&D update
Alvotech reports positive results for AVT03, potential biosimilar to Prolia and Xgeva